Zydus Lifesciences receives USFDA EIR for Baddi facility

Zydus Lifesciences announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its manufacturing facility located at Baddi, Himachal Pradesh.

The inspection at the facility was conducted by the USFDA from 4 August to 13 August 2025. Following the review, the agency has classified the facility as Voluntary Action Indicated (VAI), and the inspection has been concluded as closed by the USFDA.

The EIR has classified the facility as Voluntary Action Indicated (VAI). The USFDA has concluded this inspection as closed.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company?s consolidated net profit rose 3.3% to Rs 1,466.80 crore on a 7% rise in revenue from operations to Rs 6,467 crore in Q1 FY26 over Q1 FY25.

The counter rose 0.04% to Rs 1,001.80 on the BSE.

Powered by Capital Market - Live News